| __timestamp | Blueprint Medicines Corporation | Intra-Cellular Therapies, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 7890000 | 10337679 |
| Thursday, January 1, 2015 | 14456000 | 18187286 |
| Friday, January 1, 2016 | 19218000 | 24758063 |
| Sunday, January 1, 2017 | 27986000 | 23666957 |
| Monday, January 1, 2018 | 47928000 | 30099855 |
| Tuesday, January 1, 2019 | 96388000 | 64947625 |
| Wednesday, January 1, 2020 | 157743000 | 186363444 |
| Friday, January 1, 2021 | 195293000 | 272611040 |
| Saturday, January 1, 2022 | 237374000 | 358782000 |
| Sunday, January 1, 2023 | 295141000 | 409864000 |
| Monday, January 1, 2024 | 359272000 |
Data in motion
In the dynamic world of biotechnology, understanding financial trends is crucial for investors and stakeholders. This analysis delves into the Selling, General, and Administrative (SG&A) expenses of two pioneering companies: Intra-Cellular Therapies, Inc. and Blueprint Medicines Corporation, from 2014 to 2023. Over this period, Intra-Cellular Therapies, Inc. saw a staggering increase in SG&A expenses, growing nearly 40 times from 2014 to 2023. Blueprint Medicines Corporation also experienced a significant rise, with expenses increasing by approximately 37 times. This upward trend reflects the companies' aggressive strategies in research, development, and market expansion. Notably, by 2023, Intra-Cellular Therapies, Inc.'s SG&A expenses surpassed Blueprint Medicines Corporation by about 39%, highlighting its robust growth trajectory. These insights offer a glimpse into the financial strategies driving innovation in the biotech sector.
Who Optimizes SG&A Costs Better? AbbVie Inc. or Blueprint Medicines Corporation
Bristol-Myers Squibb Company and Blueprint Medicines Corporation: SG&A Spending Patterns Compared
Who Optimizes SG&A Costs Better? Gilead Sciences, Inc. or Intra-Cellular Therapies, Inc.
Comparing SG&A Expenses: Regeneron Pharmaceuticals, Inc. vs Blueprint Medicines Corporation Trends and Insights
Operational Costs Compared: SG&A Analysis of Intra-Cellular Therapies, Inc. and Bio-Techne Corporation
Intra-Cellular Therapies, Inc. and TG Therapeutics, Inc.: SG&A Spending Patterns Compared
Breaking Down SG&A Expenses: Intra-Cellular Therapies, Inc. vs Verona Pharma plc
Intra-Cellular Therapies, Inc. vs ADMA Biologics, Inc.: SG&A Expense Trends
Comparing SG&A Expenses: Intra-Cellular Therapies, Inc. vs Geron Corporation Trends and Insights
Intra-Cellular Therapies, Inc. vs Xencor, Inc.: SG&A Expense Trends
Blueprint Medicines Corporation and Bausch Health Companies Inc.: SG&A Spending Patterns Compared
Blueprint Medicines Corporation vs Taro Pharmaceutical Industries Ltd.: SG&A Expense Trends